Study of GS-0151 in Participants With Rheumatoid Arthritis
Phase 1
75
about 1.9 years
18–75
15 sites in AL, CA, FL +6
About this study
Researchers are testing a treatment called GS-0151 to see if it's safe and how well the body absorbs, changes, distributes, and eliminates it. The trial will last for 686 days and involve approximately 75 participants with rheumatoid arthritis.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take GS-0151
- 2.Take Placebo
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Cohort 1, 2 and 3: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs), Cohorts 1, 2 and 3: Percentage of Participants Experiencing Serous Adverse Events (SAEs) and Adverse Events (AEs) Leading to Study Discontinuation, Cohorts 1, 2 and 3: Serum Cmax, Following the Last Dose of GS-0151, Cohorts 1, 2 and 3: Serum Tmax Following the Last Dose of GS-0151
Secondary: Cohort 3: Change From Baseline in Disease Activity Score for 28 Joint Count Using C-Reactive Protein (DAS28-CRP) at Week 12 in Participants With Moderately to Severely Active RA
Immune